US Stock MarketDetailed Quotes
BLUE bluebird bio
- 0.923
- +0.010+1.13%
Close Apr 26 16:00 ET
- 0.920
- -0.003-0.30%
Post 17:57 ET
177.86MMarket Cap-1464P/E (TTM)
0.946High0.893Low5.16MVolume0.910Open0.913Pre Close4.74MTurnover2.69%Turnover RatioLossP/E (Static)192.74MShares5.53052wk High0.80P/B177.03MFloat Cap0.87952wk Low--Dividend TTM191.84MShs Float152.883Historical High--Div YieldTTM5.79%Amplitude0.879Historical Low0.919Avg Price1Lot Size
bluebird bio Stock Forum
Sign in to post a comment
Rumor spike?
$bluebird bio(BLUE.US$ Watching Bluebird Bio; Shares Spike Higher As Traders Circulating Unconfirmed Rumor Suggesting "Lyfgenia Is Among 8 New Therapies In The Running To Receive NTAP Designations At The Start Of FY25. The Emphasis On Supporting Access For SCD Therapies Across HHS Leaves Little Doubt That The New Therapy Will Qualify"
3
2
$bluebird bio(BLUE.US$
NEWS
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
bluebird bio, Inc. (BLUE) approved inducement grants of 102,700 RSUs to twelve new employees. The RSUs vest equally over four years, in line with NASDAQ rules.
NEWS
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
bluebird bio, Inc. (BLUE) approved inducement grants of 102,700 RSUs to twelve new employees. The RSUs vest equally over four years, in line with NASDAQ rules.
$bluebird bio(BLUE.US$ Accounting errors they say caused the restatement! So who pays for people’s losses because they went with the original numbers? Hehehe
1
4
Update
$bluebird bio(BLUE.US$ bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
- Cash runway through Q1 2026 following announcement of a $175 million term loan facility with Hercules Capital -
- 9 patient starts to date in 2024 (7 ZYNTEGLO, 2 SKYSONA); 85 to 105 patient starts anticipated across the portfolio in 2024 -
- First government outcomes-based agreement for sickle cell disease signed with Michigan Medicaid -
- 62 qualified...
- Cash runway through Q1 2026 following announcement of a $175 million term loan facility with Hercules Capital -
- 9 patient starts to date in 2024 (7 ZYNTEGLO, 2 SKYSONA); 85 to 105 patient starts anticipated across the portfolio in 2024 -
- First government outcomes-based agreement for sickle cell disease signed with Michigan Medicaid -
- 62 qualified...
News
$bluebird bio(BLUE.US$ bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
3 MINUTES AGO, 8:00 AM EDT
VIA BUSINESSWIRE
3 MINUTES AGO, 8:00 AM EDT
VIA BUSINESSWIRE
2
6
Just a thought!
$bluebird bio(BLUE.US$ With all the 13G and G/A filed recently. Im thinking that news of LOVO-CEL Commercial launch could be coming soon? That sure would increase the company’s financial position! Hehehe
3
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
72812736 : 一通狂涨，又跌回来了
TrytosaveabitOP 72812736: Shorts took advantage of the PI and not enough volume to keep the buy pressure on it!